Supply Chain Issues - Revision history

KateGenevieve: /* Common Supply Chain Challenges during the Pandemic */

2024-07-14T22:22:48Z

Common Supply Chain Challenges during the Pandemic

← Older revision		Revision as of 22:22, 14 July 2024
Line 24:		Line 24:
	Asthma and COPD medications, such as albuterol inhalers.		Asthma and COPD medications, such as albuterol inhalers.

	==== Personal protective equipment (PPE) ~~and hand sanitiser~~====		==== Personal protective equipment (PPE)====
	~~Sanitiser, masks~~, N95 respirators and surgical masks crucial for healthcare workers.		Masks, N95 respirators and surgical masks crucial for healthcare workers.

			====Hand Sanitiser====
			Medical-grade hand sanitisers and alcohol-based hand sanitiser recommended by the World Health Organisation (WHO) for their effectiveness in killing bacteria. The extreme shortage led some distilleries to start production of their own brands of hand sanitiser, and a relaxation in regulation to allow for rapid production and distribution.

	===Ongoing Supply Chain Challenges===		===Ongoing Supply Chain Challenges===

KateGenevieve at 22:17, 14 July 2024

2024-07-14T22:17:09Z

← Older revision		Revision as of 22:17, 14 July 2024
Line 67:		Line 67:
	'''		'''
	Routine vaccines, such as flu vaccines, were in short supply due to the focus and attention shifting to COVID-19 vaccine production.		Routine vaccines, such as flu vaccines, were in short supply due to the focus and attention shifting to COVID-19 vaccine production.

			===Long-term Changes in Medical Supply Chains===

			Different countries responded to the pandemic with varying levels of leadership, governance, and preparedness. Public health measures and government communication also differed significantly. The pandemic is leading to changes in how supplies are produced and distributed based on what was learned from these varied approaches. Regulatory frameworks are adapting to factor in precaution and to allow more flexibility in future crises.

			There is also learning from from successful initiatives, such as Singapore’s national stockpile of PPE and medical products to last for up to 6 months, drawing on the lessons learned when responding to the SARS (Severe Acute Respiratory Syndrome) outbreak in 2003 <ref>Chua, A. Q. et al. Health system resilience in managing the COVID-19 pandemic: lessons from Singapore. BMJ Glob. Health 5, e003317 (2020). https://gh.bmj.com/content/5/9/e003317 </ref>

	==Citations==		==Citations==

	<references/>		<references/>

KateGenevieve at 22:02, 14 July 2024

2024-07-14T22:02:25Z

← Older revision		Revision as of 22:02, 14 July 2024
Line 4:		Line 4:

	The situation exacerbates existing global health inequities.<ref>Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y</ref> Whilst supply shortages, uncertain medical stocks and counterfeit medical essentials are global problems, developed countries experience disruptions in supply chains for medications that were previously available, whilst lower income countries face chronic shortages and limited access to essential drugs, and others historically lacked access to certain essential medications.		The situation exacerbates existing global health inequities.<ref>Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y</ref> Whilst supply shortages, uncertain medical stocks and counterfeit medical essentials are global problems, developed countries experience disruptions in supply chains for medications that were previously available, whilst lower income countries face chronic shortages and limited access to essential drugs, and others historically lacked access to certain essential medications.

			===Common Supply Chain Challenges during the Pandemic ===

			Essential medicines and products experienced supply challenges during the Pandemic in connection with lockdowns and transportation issues, manufacturing challenges, and increased demand.

			==== Antibiotics ====
			Penicillin and its derivatives.

			==== Critical Care and Anaesthesia====
			Medications used in intensive care units (ICUs) for intubated patients and during surgical procedures.

			==== Sedatives and Pain Management Medications====
			Opioid and standard non-opioid pain relievers.

			==== Ventilator Supplies====
			Components and medications needed for ventilator use.

			==== Inhalers====
			Asthma and COPD medications, such as albuterol inhalers.

			==== Personal protective equipment (PPE) and hand sanitiser====
			Sanitiser, masks, N95 respirators and surgical masks crucial for healthcare workers.

	===Ongoing Supply Chain Challenges===		===Ongoing Supply Chain Challenges===

KateGenevieve: /* Introduction */

2024-07-14T21:49:01Z

Introduction

← Older revision		Revision as of 21:49, 14 July 2024
Line 3:		Line 3:
	The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities.		The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities.

	The situation exacerbates existing global health inequities.<ref>Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y</ref> Whilst shortages ~~and~~ uncertain medical stocks, and counterfeit medical essentials, are problems ~~across the board. Developed~~ countries experience disruptions in supply chains for medications that were previously available, whilst lower income countries face chronic shortages and limited access to essential drugs, and others historically ~~lacking~~ access to certain essential medications.		The situation exacerbates existing global health inequities.<ref>Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y</ref> Whilst supply shortages, uncertain medical stocks and counterfeit medical essentials are global problems, developed countries experience disruptions in supply chains for medications that were previously available, whilst lower income countries face chronic shortages and limited access to essential drugs, and others historically lacked access to certain essential medications.

	===Ongoing Supply Chain Challenges===		===Ongoing Supply Chain Challenges===

KateGenevieve: /* Introduction */

2024-07-14T21:47:33Z

Introduction

← Older revision		Revision as of 21:47, 14 July 2024
Line 3:		Line 3:
	The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities.		The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities.

	The situation exacerbates existing global health inequities. <ref>Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y</ref> Whilst shortages and uncertain medical stocks, and counterfeit medical essentials, are problems across the board. Developed countries experience disruptions in supply chains for medications that were previously available, whilst lower income countries face chronic shortages and limited access to essential drugs, and others historically lacking access to certain essential medications.		The situation exacerbates existing global health inequities.<ref>Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y</ref> Whilst shortages and uncertain medical stocks, and counterfeit medical essentials, are problems across the board. Developed countries experience disruptions in supply chains for medications that were previously available, whilst lower income countries face chronic shortages and limited access to essential drugs, and others historically lacking access to certain essential medications.

	===Ongoing Supply Chain Challenges===		===Ongoing Supply Chain Challenges===

KateGenevieve at 21:46, 14 July 2024

2024-07-14T21:46:59Z

← Older revision		Revision as of 21:46, 14 July 2024
Line 1:		Line 1:
	Introduction		=== Introduction===

	The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities.		The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities.

KateGenevieve at 21:46, 14 July 2024

2024-07-14T21:46:24Z

← Older revision		Revision as of 21:46, 14 July 2024
Line 1:		Line 1:
	The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities. Problems with shortages and uncertain medical stocks and reports of counterfeit medical essentials continue.		Introduction

	Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y		The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities.

			The situation exacerbates existing global health inequities. <ref>Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y</ref> Whilst shortages and uncertain medical stocks, and counterfeit medical essentials, are problems across the board. Developed countries experience disruptions in supply chains for medications that were previously available, whilst lower income countries face chronic shortages and limited access to essential drugs, and others historically lacking access to certain essential medications.

	===Ongoing Supply Chain Challenges===		===Ongoing Supply Chain Challenges===
Line 44:		Line 46:
	Routine vaccines, such as flu vaccines, were in short supply due to the focus and attention shifting to COVID-19 vaccine production.		Routine vaccines, such as flu vaccines, were in short supply due to the focus and attention shifting to COVID-19 vaccine production.

	==Citations===		==Citations==

			<references/>

KateGenevieve at 21:36, 14 July 2024

2024-07-14T21:36:47Z

← Older revision		Revision as of 21:36, 14 July 2024
Line 23:		Line 23:
	Chemotherapy agents and supportive care medications that manage side effects of chemotherapy, like anti-nausea drugs.		Chemotherapy agents and supportive care medications that manage side effects of chemotherapy, like anti-nausea drugs.

	~~====~~ '''HRT Medications		'''HRT Medications
	''' ~~====~~		'''
	The supply of Hormone Replacement Therapies (HRT), including estrogen and progesterone products, was disrupted affecting individuals relying on these treatments for menopausal symptoms, gender-affirming care, and other hormonal imbalances.		The supply of Hormone Replacement Therapies (HRT), including estrogen and progesterone products, was disrupted affecting individuals relying on these treatments for menopausal symptoms, gender-affirming care, and other hormonal imbalances.

KateGenevieve: /* Ongoing Supply Chain Challenges */

2024-07-14T21:36:23Z

Ongoing Supply Chain Challenges

← Older revision		Revision as of 21:36, 14 July 2024
Line 23:		Line 23:
	Chemotherapy agents and supportive care medications that manage side effects of chemotherapy, like anti-nausea drugs.		Chemotherapy agents and supportive care medications that manage side effects of chemotherapy, like anti-nausea drugs.

	'''HRT Medications		==== '''HRT Medications
	'''		''' ====
	The supply of Hormone ~~replacement therapies~~ (HRT), including estrogen and progesterone products, was disrupted affecting individuals relying on these treatments for menopausal symptoms, gender-affirming care, and other hormonal imbalances.		The supply of Hormone Replacement Therapies (HRT), including estrogen and progesterone products, was disrupted affecting individuals relying on these treatments for menopausal symptoms, gender-affirming care, and other hormonal imbalances.

	'''Mental Health Medications		'''Mental Health Medications

KateGenevieve: /* Ongoing Supply Chain Challenges */

2024-07-14T21:35:49Z

Ongoing Supply Chain Challenges

← Older revision		Revision as of 21:35, 14 July 2024
Line 5:		Line 5:
	===Ongoing Supply Chain Challenges===		===Ongoing Supply Chain Challenges===

	Vulnerabilities in the pharmaceutical supply chain are ongoing~~, with shortages~~ in raw materials, logistical and manufacturing challenges, contribute to ongoing, significant shortages in various drugs and supplies.		Vulnerabilities in the pharmaceutical supply chain are ongoing. Shortages in raw materials and logistical and manufacturing challenges contribute to ongoing, significant shortages in various drugs and supplies.

	'''Generic sterile injectable medications		'''Generic sterile injectable medications